Literature DB >> 26797716

Catalyst-free multicomponent synthesis of novel adamantyl-containing tetrahydropyrimidine carboxylates.

Utpalparna Kalita1, Shunan Kaping1, Jai Narain Vishwakarma2.   

Abstract

[Formula: see text]-Enaminoesters were generated in situ by the reaction of aliphatic or aromatic primary amines to electron-deficient alkynes, dimethyl acetylenedicarboxylate, and methyl propiolate. [Formula: see text]-Enaminoesters thus formed were reacted with 1-adamantanamine and formaldehyde in methanol to give novel molecular hybrids: dimethyl 3-((3s,5s,7s)-adamantan-1-yl)-1-(alkyl/aralkyl/aryl)-1,2,3,4-tetrahydropyrimidine-5,6-dicarboxylates (5a-j) and methyl 3-((3s,5s,7s)-adamantan-1-yl)-1-(alkyl/aralkyl/aryl)-1,2,3,4-tetrahydropyrimidine-5-carboxylates (9a-j). The structures of the molecular hybrids have been established based on the spectral and analytical data. Structural confirmation of the products was done by X-ray crystallography of 5d as a representative product of the series.

Entities:  

Keywords:  -Enaminoesters; 1-Adamantanamine; Cyclization; Heterocycles; MCRs; Multicomponent reactions; Tetrahydropyrimidine

Mesh:

Substances:

Year:  2016        PMID: 26797716     DOI: 10.1007/s11030-015-9653-8

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  11 in total

1.  Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

Authors:  Zhanqian Yu; Anu R Sawkar; Lisa J Whalen; Chi-Huey Wong; Jeffery W Kelly
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor.

Authors:  Lulu Farhana; Marcia I Dawson; Mark Leid; Li Wang; David D Moore; Gang Liu; Zeben Xia; Joseph A Fontana
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 4.  The many faces of the adamantyl group in drug design.

Authors:  Joe Liu; Daniel Obando; Vivian Liao; Tulip Lifa; Rachel Codd
Journal:  Eur J Med Chem       Date:  2011-02-03       Impact factor: 6.514

5.  Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation.

Authors:  Lulu Farhana; Marcia I Dawson; Joseph A Fontana
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

6.  Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1.

Authors:  Jason Long; Tejas Manchandia; Kechen Ban; Shan Gao; Claudia Miller; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2006-08-19       Impact factor: 3.333

7.  The pharmacology of aminoadamantane nitrates.

Authors:  Yuqiang Wang; Jerry Eu; Mark Washburn; Tong Gong; H-S Vincent Chen; W Larrick James; Stuart A Lipton; Jonathan S Stamler; Gregory T Went; Seth Porter
Journal:  Curr Alzheimer Res       Date:  2006-07       Impact factor: 3.498

8.  Synthesis, antimicrobial and antiviral testing of some new 1-adamantyl analogues.

Authors:  Ghada S Hassan; Ali A El-Emam; Laila M Gad; Alaa Eldin M Barghash
Journal:  Saudi Pharm J       Date:  2010-05-31       Impact factor: 4.330

9.  Synthesis and antiviral activity of metabolites of rimantadine.

Authors:  P S Manchand; R L Cerruti; J A Martin; C H Hill; J H Merrett; E Keech; R B Belshe; E V Connell; I S Sim
Journal:  J Med Chem       Date:  1990-07       Impact factor: 7.446

10.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

Authors:  Edwin B Villhauer; John A Brinkman; Goli B Naderi; Bryan F Burkey; Beth E Dunning; Kapa Prasad; Bonnie L Mangold; Mary E Russell; Thomas E Hughes
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.